T. Dahring

发表

PDGF receptor protein tyrosine kinase expression in the balloon-injured rat carotid artery.

R. Panek, J. Keiser, B. Olszewski, 1997, Arteriosclerosis, thrombosis, and vascular biology.

The discovery of glycine and related amino acid-based factor Xa inhibitors.

Mostofa A Hena, V. Sahasrabudhe, E. Zhang, 2006, Bioorganic & medicinal chemistry.

The Discovery of (2R,4R)‐N‐(4‐chlorophenyl)‐N‐ (2‐fluoro‐4‐(2‐oxopyridin‐1(2H)‐yl)phenyl)‐4‐methoxypyrrolidine‐1,2‐dicarboxamide (PD 0348292), an Orally Efficacious Factor Xa Inhibitor

L. Chi, E. Zhang, Tom McClanahan, 2007, Chemical biology & drug design.

2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.

D. Boschelli, A. Doherty, H. D. Showalter, 1998, Journal of medicinal chemistry.

Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors.

A. Doherty, D. W. Fry, H. D. Showalter, 1997, Journal of medicinal chemistry.

Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors.

D. Boschelli, A. Doherty, H. D. Showalter, 1998, Journal of medicinal chemistry.

Soluble 2-substituted aminopyrido[2,3-d]pyrimidin-7-yl ureas. Structure-activity relationships against selected tyrosine kinases and exploration of in vitro and in vivo anticancer activity.

A. Doherty, H. D. Showalter, J. M. Hamby, 2001, Journal of medicinal chemistry.

In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor.

A. Doherty, J. M. Hamby, R. Panek, 1997, The Journal of pharmacology and experimental therapeutics.

Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smooth muscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor.

J. M. Hamby, A. Kraker, R. Panek, 1997, The Journal of pharmacology and experimental therapeutics.

Design of peptidomimetics that inhibit the association of phosphatidylinositol 3-kinase with platelet-derived growth factor-beta receptor and possess cellular activity.

D. R. Holland, A. Doherty, R. Panek, 1998, Journal of medicinal chemistry.

2-Substituted Aminopyrido[2,3- d ]pyrimidin-7(8 H )-ones. Structure−Activity Relationships Against Selected Tyrosine Kinases and in Vitro and in Vivo Anticancer Activity

D. Boschelli, A. Doherty, H. D. Showalter, 1998 .

In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.

R. Panek, G. Lu, C. Connolly, 1998, The Journal of pharmacology and experimental therapeutics.

Inhibition of FGF-1 receptor tyrosine kinase activity by PD 161570, a new protein-tyrosine kinase inhibitor.

A. Doherty, R. Panek, G. Lu, 1997, Life sciences.